<- Go Home
LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Market Cap
$377.2M
Volume
460.5K
Cash and Equivalents
$269.7M
EBITDA
-$21.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$20.25
52 Week Low
$13.36
Dividend
N/A
Price / Book Value
1.22
Price / Earnings
-20.06
Price / Tangible Book Value
1.22
Enterprise Value
$66.4M
Enterprise Value / EBITDA
-3.13
Operating Income
-$22.1M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$314.5M
Debt
$3.7M
Equity
$310.2M
Revenue
N/A
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium